While a prior publication demonstrates that pharmacological targeting of HUNK can impede tumor growth, those studies were performed in a resistant HER2-positive (HER2+) breast cancer cell model and not a metastatic breast cancer model [26]. Here, ERBB2 is linked to neoplasm.